evaluation of the efficacy of one dose of autogenous mjprrs vaccine in nursery pigs
DESCRIPTION
Evaluation of the efficacy of one dose of autogenous MJPRRS vaccine in nursery pigs. Dr. Mark Wagner, DVM Fairmont Veterinary Clinic Fairmont, MN. Purpose of study. - PowerPoint PPT PresentationTRANSCRIPT
Evaluation of the efficacy of one dose of autogenous MJPRRS vaccine in
nursery pigs
Dr. Mark Wagner, DVMFairmont Veterinary Clinic
Fairmont, MN
Purpose of study
• Gain a better understanding of the role and efficacy of using the autogenous MJPRRS vaccine in controlling or managing PRRS virus
Trial data to be presented
• Trial #1– Vaccination of PRRS naïve pigs at 21 days of age
and challenge with field virus at 32 days post vaccination
• Trial #2– Similar repeat of trial #1, pigs challenged at 28
days post vaccination
• Trial #3– Vaccination of PRRS viremic pigs at peak viremia
Trial design
• Challenge material– Virulent field virus with a 1-18-2 RFLP
• Group D-4 under MJPRRS virus grouping system
• Preparation of virus material– A 21 day old PRRS naïve pig inoculated with the 1-18-2 field virus– Serum collected 5 days post inoculation and frozen– An aliquot of serum inoculated on cell culture and
harvested 7 days later, then frozen
Trial design
• Analysis of challenge material– Sequencing completed to confirm 1-18-2 virus– Quantitative PRRS PCR’s completed along with
TCID50’s
Inoculum material
ORF6-copies per ml
Calculated IVP’s per ml TCID50
Serum 109 2,341 102
Cell Culture 1010 24,416 103
Trial design
• Challenge dose– Trial #1• 0.5ml IM plus 0.5ml IN (serum material = 100 viruses) (culture material = 1,000 viruses)
– Trial #2• 0.5ml IM plus 0.5ml IN (culture material = 1,000 viruses)
– Trial #3• 0.05ml IM plus 0.5ml IN (serum material = 55 viruses)
Trial design
• Vaccination protocol– Treatment group• MJPRRS
– 2ml dose that included 10% extra adjuvant (final 20%)• Mycoplasma
– 2ml dose
– Control groups• Mycoplasma
– 2ml dose
Trial design
• Data collection included– Body temperature– Virus replication based on PRRS Q-PCR’s– Mortality– Average daily gain weight
PRRS virus replication data:
Data compiled for Trial #1, Trial #2, and Trial #3
Summary PRRS virus replication in MJPRRS vaccinated compared to non-vaccinated 21 day old PRRS naïve pigs when challenged to
a field virus at 53 and 49 days old (Trial #1 & #2 data)
Serum Challenged Culture Challenged
Days Post Challenge
Vaccinated Non–Vaccinated Vaccinated Non–Vaccinated
ORF6 copies* IVP# ORF6 copies IVP ORF6 copies IVP ORF6 copies IVP
51.8 x 109 704 2.8 x 109 1,118 1.3 x 109
--------------9.3 x 108
674-----------
367
2.2 x 109
---------------8.4 x 108
867----------
328
116.4 x 107 25 2.7 x 108 106 1.1 x 108
--------------4.2 x 107
44-----------
16
2.1 x 108
---------------7.2 x 107
83----------
28
235.4 x 105 0.21 2.0 x 106 0.79 2.2 x 106
--------------5.1 x 106
0.88-----------
1.9
1.4 x 106
---------------2.1 x 106
0.50----------
0.80
* ORF6 Copies per ml by Quantitative PCR# Infective Virus Particles calculated per ml based on Q-PCR
Summary of PRRS virus replication in 26 day old PRRS viremic pigs vaccinated with MJPRRS vaccine at the peak of
viremia compared to non-vaccinated controls (Trial #3 data)
Serum Challenged then Vaccinated Non-Vaccinated
ORF6 Copies* IVP# ORF6 Copies IVP
5 Days post challenge(Day of vaccination) 3.5 x 109 1,355 3.3 x 109 1,144
7 Days post challenge(2 Days post vaccination) 5.2 x 109 2,079 5.6 x 109 2,215
14 Days post challenge(7 Days post vaccination) 3.5 x 108 103 1.2 x 109 488
24 Days post challenge(10 Days post vaccination) 1.8 x 108 55 5.5 x 108 123
* ORF6 Copies per ml by Quantitative PCR# Infective Virus Particles calculated per ml based on Q-PCR
Average daily gain data:
Data compiled for Trial #1 and Trial #2
Summary of Average Daily Gain (ADG) performance in MJPRRS vaccinated compared to non-vaccinated 21 day old PRRS naïve pigs when challenged to a field strain of
PRRS at 53 days of age (Trial #1 data)
Day 1 Day 32 post arrival Day 55 post arrival Overall
Day of Vaccination Challenged* Day 1-23 post challenge Day 1-55 arrival
Weight (Ibs) Average Average ADG Average ADG# ADG
Vaccinated 14.5 36.5 0.71 54.0 0.76 0.74
Non-Vaccinated 16.0 32.5 0.53 53.0 0.89 0.68
* All pigs challenged with PRRSv at 32 days post arrival (53 days of age)# ADG affected by mortality;
Vaccinated group, 1 of 22 dead Non-vaccinated group, 4 of 22 dead
Summary of Average Daily Gain (ADG) performance in MJPRRS vaccinated compared to non-vaccinated 21 day old PRRS naïve pigs when challenged to a field strain of PRRS at 49 days of age
(Trial #2 data)
Day 1 Day 28 post arrival
Day 40 post arrival Day 54 post arrival Overall
Day of Vaccination Challenged* Day 1 – 11 post challenge
Day 11 – 24 post challenge
Day 1-54 arrival
Weight (Ibs) Average# Average ADG Average ADG Average ADG ADG
Vaccinated 13.7 31.2 0.62 34.2 0.27 49.0 1.14 0.74
Non-vaccinated 14.2 35.5 0.76 37.6 0.19 48.0 0.80 0.52
* All pigs challenged with PRRSv at 28 days post arrival (49 days of age)
Mortality data:
Data compiled for Trial #1, Trial #2, and Trial #3
Summary of Mortality in MJPRRS vaccinated compared to non-vaccinated 21 day old pigs when challenged to a field strain of
PRRS at 53 or 49 days of age (Trial #1 and #2 data)
Trial #1Challenge material Treatment group Mortality at 23 days post challenge
SerumNon-Vaccinated 3 of 11 (27%)
Vaccinated 1 of 11 (9%)
CultureNon-Vaccinated 1 of 11 (9%)
Vaccinated 0 of 11 (0%)
Trial # 2Challenge material Treatment group Mortality at 23 days post challenge
CultureNon-Vaccinated 0 of 16 (0%)
Vaccinated 0 of 16 (0%)
Overall mortality for non-vaccinated groups, 18.2%Overall mortality for vaccinated groups, 4.5%
Summary of Mortality in 26 day old PRRS viremic pigs vaccinated with MJPRRS vaccine at peak viremia compared to non-vaccinated
controls (Trial #3 data)
Trial # 3Challenge material Treatment group Mortality at 10 days post vaccination*
SerumNon-Vaccinated 3 of 12 (25%)
Vaccinated 2 of 12 (16%)
* 15 days post challenge
Summary (I)
• Virus Replication– For trial #1, a statistical reduction in virus replication
shown between the MJPRRS vaccinates compared to the non-vaccinates at days 5 and 11 post challenge (p value = 0.04 and 0.0098, respectively)
– For trial #2, no statistical difference noted– For trial #3, a statistical reduction in virus replication
during vaccination at peak viremia at day 7 and 10 post vaccination (p value = 0.048 and 0.002, respectively)
Summary (II)
• Average Daily Gain (ADG)– For trial #1, no statistical difference noted
Numerically: Vaccinates, Day 1-23 post challenge, 0.76 Non-Vaccinates, Day 1-23 post challenge, 0.89
High mortality in non-vaccinates likely affected ADG differences in calculation
– For trial #2, A statistical difference (p value = 0.026)between MJPRRS vaccinated group vs. controls during Day 1-24
Numerically: Vaccinates, Day 1-24 post challenge, 0.74 Non-Vaccinates, Day 1-24 post challenge, 0.52
Summary (III)• Mortality– For trial #1• Vaccinates = 1 of 22 (4.5%)• Non Vaccinates = 4 of 22 (18%)
– For trial #2• No mortality in either group
– For trial #3• Vaccinates = 2 of 12 (16%)• Non Vaccinates = 3 of 12 (25%)
Conclusions• Data demonstrated that PRRS naïve or viremic pigs
were able to respond to one dose of autogenous MJPRRS vaccine with extra adjuvant.
• A reduction on virus replication was statistically demonstrated (2 of 3 trials).
• A numerical improvement in ADG was demonstrated (2 of 2 trials). A statistical difference noted also (1 of 2 trials).
• A numerical improvement in Mortality was demonstrated (2 of 3 trials).
Thank you